Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Delivering cytokine mRNA to secondary lymphoid organs for robust cancer immunotherapy.

Research square·2026

Same author

Systemically inducing trained immunity overcomes solid tumors' immunosuppressive microenvironment.

Science advances·2026

Same author

Dendrimers Improve Apolipoprotein Nanoparticle mRNA Delivery to Immune Cells.

Advanced materials (Deerfield Beach, Fla.)·2025

Same author

Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy.

Bioconjugate chemistry·2025

Same author

Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors.

Nature nanotechnology·2025

Same author

Polymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy.

Nature nanotechnology·2024

Same journal

Engineering Functional Graphenic Materials for Bone Repair.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Breaking Through the Limits: Nanomedicine at the Service of New Drug Combinations to Tackle Pancreatic Cancer.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Advances in Engineered Virus-Like Particles for Applications in Nanomedicine.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Lipid- and Polymer-Based Nanoscale Delivery of Anti-Aging Phytochemicals.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Nano-Enabled Toxicity of Pharmaceutical Excipients.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

Same journal

Advances in Self-Assembly Artificial Chaperone for Protein Folding Regulation.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Engineering Lipid Nanoparticles for mRNA Immunotherapy.

Robby Zwolsman¹, Youssef B Darwish¹, Ewelina Kluza¹

¹Laboratory of Chemical Biology, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, the Netherlands.

Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology

|April 8, 2025

Summary

This summary is machine-generated.

Messenger RNA (mRNA) therapies, delivered via lipid nanoparticles (LNPs), show promise for various diseases. Further development is needed to optimize LNP-mRNA delivery for widespread therapeutic use.

Keywords:

immunotherapy lipid nanoparticles (LNP)messenger RNA (mRNA)

More Related Videos

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Related Experiment Videos

Last Updated: Jun 21, 2026

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells

Published on: June 10, 2022

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing

Published on: January 20, 2023

Area of Science:

Biotechnology
Immunology
Nanomedicine

Background:

Messenger RNA (mRNA) therapeutics offer a versatile platform for genetic instructions.
Chemical modifications and nanotechnology are crucial for mRNA stability and delivery.
Lipid nanoparticles (LNPs) are the leading delivery system for mRNA therapeutics.

Purpose of the Study:

To review the current state of LNP-mRNA technology for therapeutic applications.
To discuss the potential of LNP-mRNA in immunotherapy, including vaccination, oncology, and autoimmune disorders.
To identify challenges and future directions for LNP-mRNA development.

Main Methods:

Review of existing literature on LNP-mRNA technology.
Analysis of LNP-mRNA applications in vaccination and immunotherapy.
Discussion of challenges in LNP-mRNA delivery and immunostimulatory effects.

Main Results:

LNPs are highly effective for mRNA delivery, particularly for vaccines and hepatic applications.
LNP-mRNA holds significant potential for diverse immunotherapeutic strategies.
Key challenges include controlling biodistribution and mitigating immunostimulatory effects.

Conclusions:

LNP-mRNA technology is a rapidly advancing field with broad therapeutic potential.
Overcoming challenges in delivery and immunogenicity is critical for clinical translation.
Advanced methods like library screening and machine learning will drive future innovations.